Double attack: new CAR t therapy targets two cancer proteins in aggressive lymphoma

NCT ID NCT05826535

Recruiting now Disease control Sponsor: Lyell Immunopharma, Inc. Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 33 times

Summary

This study tests a new treatment called rondecabtagene autoleucel (ronde-cel) for people with aggressive B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. Ronde-cel is a CAR T-cell therapy that targets two proteins (CD19 and CD20) on cancer cells. The trial has two phases: Phase 1 checks safety and the right dose, and Phase 2 measures how well it works. About 270 adults will take part across multiple centers.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Atrium Health Wake Forest Baptist
RECRUITING

Winston-Salem, North Carolina, 27157, United States
Augusta University Medical Center
RECRUITING

Augusta, Georgia, 30912, United States
Baylor University Medical Center
RECRUITING

Dallas, Texas, 75246, United States
Cedars-Sinai Medical Center
RECRUITING

Los Angeles, California, 90048, United States
Cleveland Clinic
RECRUITING

Cleveland, Ohio, 44195, United States
Colorado Blood Cancer Institute
RECRUITING

Denver, Colorado, 80218, United States
Corewell Health
RECRUITING

Grand Rapids, Michigan, 49503, United States
David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10021, United States
Huntsman Cancer Institute
RECRUITING

Salt Lake City, Utah, 84112, United States
Indiana Blood and Marrow Transplantation
RECRUITING

Indianapolis, Indiana, 46237, United States
Intermountain Healthcare
RECRUITING

Salt Lake City, Utah, 84143, United States
John Theurer Cancer Center Hackensack University Medical Center
RECRUITING

Hackensack, New Jersey, 07601, United States
Lehigh Valley Topper Cancer Center Institute
RECRUITING

Allentown, Pennsylvania, 18103, United States
Louisiana State University Health Sciences Center
RECRUITING

Shreveport, Louisiana, 71130, United States
Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States
Medstar Georgetown University Hospital
RECRUITING

Washington D.C., District of Columbia, 20007, United States
Montefiore Medical Center
RECRUITING

The Bronx, New York, 10461, United States
Roswell Park Comprehensive Cancer Center
RECRUITING

Buffalo, New York, 14263, United States
Royal Perth Hospital
RECRUITING

Perth, Western Australia, 6000, Australia
Scripps Clinic
RECRUITING

San Diego, California, 92037, United States
Texas Transplant Institute
RECRUITING

San Antonio, Texas, 78229, United States
The Alfred Hospital
RECRUITING

Melbourne, 3004, Australia
Thomas Jefferson University
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of California, Los Angeles (UCLA) Medical Center
RECRUITING

Los Angeles, California, 90095, United States
University of California-Irvine Medical Center
RECRUITING

Irvine, California, 92697, United States
University of Cincinnati (UC) Physicians Company, LLC
RECRUITING

Cincinnati, Ohio, 45267, United States
University of Iowa
RECRUITING

Iowa City, Iowa, 52242, United States
University of Louisville Brown Cancer Center
RECRUITING

Louisville, Kentucky, 40202, United States
University of Nebraska Medical Center
RECRUITING

Omaha, Nebraska, 68198, United States
University of New Mexico Comprehensive Cancer Center
RECRUITING

Albuquerque, New Mexico, 87131, United States
Vanderbilt University Medical Center
RECRUITING

Nashville, Tennessee, 37212, United States
Virginia Commonwealth University-Massey Cancer Center
RECRUITING

Richmond, Virginia, 23298, United States
Virginia Oncology Associates
RECRUITING

Norfolk, Virginia, 24502, United States
West Penn Hospital
RECRUITING

Pittsburgh, Pennsylvania, 15224, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Rondecabtagene autoleucel (ronde-cel), a CAR T-cell therapy that targets two proteins (CD19 and CD20) on lymphoma cells, given with conditioning chemotherapy (fludarabine and cyclophosphamide)

What this could lead to

If successful, this could offer a new treatment option for people with aggressive B-cell lymphoma that has not responded to other therapies.

What could go wrong

This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to everyone. CAR T-cell therapies can cause serious side effects like cytokine release syndrome and neurological problems.

Conditions

The condition(s) this trial relates to.

B-cell neoplasm diffuse large B-cell lymphoma Disease Attributes follicular lymphoma immune system disorder lymphoma non-Hodgkin lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARGE B-CELL LYMPHOMA LARGE B-CELL LYMPHOMA NON HODGKIN LYMPHOMA REFRACTORY NON-HODGKIN LYMPHOMA RELAPSED NON-HODGKIN LYMPHOMA